ArticleJournal of pharmaceutical health care and sciences2026
Investigating rituximab-induced infusion-related reactions in patients with non-Hodgkin lymphoma, with a focus on follicular lymphoma: a retrospective observational study.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of Rituximab-Associated Hypersensitivity Reactions with Successfully Applied Desensitization Protocols: A Clinical Experience of 46 Infusions in 11 Patients.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe incidence of infusion-related reactions (IRRs) caused by rituximab is very high, and many studies have explored factors related to the onset of IRR; however, most analyses have been conducted on a mixed range of disease indications. This study aimed to investigate rituximab-induced IRR in patients with non-Hodgkin lymphoma (NHL), particularly follicular lymphoma (FL), and examine the factors related to its occurrence.
methodsData on sociodemographic and blood test findings were collected on the closest possible date prior to rituximab administration. Cytokine/chemokine levels in the blood samples were measured before the drug administration. During rituximab administration, vital signs, including pulse, oxygen saturation, respiratory rate, and body temperature, were carefully monitored. IRRs were defined as adverse reactions that occurred within 24 hours of drug administration, the grades of which were assessed using the Common Terminology Criteria for Adverse Events, version 5.0.
resultsIRRs were reported in 119/252 NHL cases (47.2%), with incidences of 36/61 (59.0%) FL cases and 48/119 (40.3%) diffuse large B-cell lymphoma (DLBCL) cases; the incidence of IRR was significantly higher in FL (p = 0.0174). Logistic regression analysis in FL revealed a significant correlation between IRR expression and lymphocyte counts of ≥ 1,600/µL (odds ratio 14.0, p = 0.0162). Additionally, interferon-γ (p = 0.0262), chemokine ligand 26 (p = 0.0394), and vascular endothelial growth factor (p = 0.0359) levels in FL.
conclusionsThe incidence of IRR differed significantly between patients with FL and those with DLBCL. In FL, rituximab is administered while monitoring the disease condition and when the tumor burden is relatively large, which is thought to increase the frequency of IRR, suggesting that lymphocyte count can lead to effective prediction. The occurrence of IRR can be predicted by measuring the blood cytokine and chemokine levels before rituximab treatment, leading to the provision of safe and useful treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.